FMFC:NASDAQKandal M Venture Limited Analysis
Data as of 2026-06-17 - not real-time
$0.29
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Kandal M Venture Limited (FMFC) is trading at $0.2896, a sharp drop from the prior close of $0.3402, leaving the price well below its 20‑day (≈$0.38) and 50‑day (≈$0.39) simple moving averages. The RSI of 29.5 signals an oversold condition, yet the MACD histogram remains negative and the MACD line sits beneath its signal, confirming a bearish momentum. Volume has been increasing, suggesting heightened trader interest despite the downtrend, while a 30‑day volatility of over 75% underscores a highly erratic price path. The stock’s beta of 1.10 points to slightly higher sensitivity to market swings, and the historic max drawdown of roughly 98% highlights the potential for severe capital erosion.
Fundamentally, FMFC reports a 17% revenue contraction and negative profit margins, with operating cash flow and free cash flow both in the red. The balance sheet shows modest cash reserves ($1.73M) against a relatively high debt‑to‑equity ratio of 1.62, and equity is eroding as reflected by negative ROE and ROA. Valuation multiples are low – a price‑to‑book of 0.66 and price‑to‑sales of 0.34 – implying the market may be pricing in distress rather than intrinsic value. No dividend is paid, and analysts have not issued coverage, leaving investors without external guidance. Overall, the combination of a bearish technical setup, deteriorating fundamentals, and elevated risk metrics suggests caution.
Fundamentally, FMFC reports a 17% revenue contraction and negative profit margins, with operating cash flow and free cash flow both in the red. The balance sheet shows modest cash reserves ($1.73M) against a relatively high debt‑to‑equity ratio of 1.62, and equity is eroding as reflected by negative ROE and ROA. Valuation multiples are low – a price‑to‑book of 0.66 and price‑to‑sales of 0.34 – implying the market may be pricing in distress rather than intrinsic value. No dividend is paid, and analysts have not issued coverage, leaving investors without external guidance. Overall, the combination of a bearish technical setup, deteriorating fundamentals, and elevated risk metrics suggests caution.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish technical indicators (price below SMAs, negative MACD)
- Accelerating volume amid price decline
- High short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential price stabilization near support at $0.24
- Low valuation multiples offering a floor
- Continued earnings losses limiting upside
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Fundamental turnaround required for sustainable growth
- Exposure to emerging‑market regulatory and currency risks
- Absence of dividend income and analyst coverage
Key Metrics & Analysis
Financial Health
Revenue Growth-17.00%
Profit Margin-1.75%
ROE-6.21%
ROA-2.31%
Debt/Equity1.61
P/B Ratio0.7
Op. Cash Flow$-1916105
Free Cash Flow$-521049
Technical Analysis
TrendBearish
RSI29.5
Support$0.24
Resistance$0.44
MA 20$0.38
MA 50$0.39
MA 200$2.69
MACDBearish
VolumeIncreasing
Fear & Greed Index90.23
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta1.10
Volatility75.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.